Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion
Information source: Hadassah Medical Organization
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Central Retinal Vein Occlusion
Intervention: Retinal endo vascular surgery (Procedure)
Phase: N/A
Status: Not yet recruiting
Sponsored by: Hadassah Medical Organization Official(s) and/or principal investigator(s):
Michael halpert, Study Chair, Affiliation: Hadassah Medical Organization
Overall contact:
Michael Halpert, MD., Phone: 00972507874385, Email: halpert@cc.huji.ac.il
Summary
Patients with Central Retinal Vein Occlusion will undergo vitrectomy, a small needle of about
71 micron will enter a branch retinal vein and TPA will be injected into the obstracted
vein.
Clinical Details
Study design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment
Primary outcome: Visual acuityAmount of macular edema.
Detailed description:
Patients with Central Retinal Vein Occlusion less than 6 month duration and reduction of
vision to 6/21 will go OCT and FANG examinations.
Patient will be operated vitrectomy, and a branch retinal vein will be punctured by small
needle and rTPA 200mcg/ml will be injected to the vein.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- crvo less than 6 month
- Visual Acuity less than 6/21
- No prior eye surgery except cataract.
Exclusion Criteria:
- Retinal/iris neovascularization
Locations and Contacts
Michael Halpert, MD., Phone: 00972507874385, Email: halpert@cc.huji.ac.il Additional Information
Starting date: October 2006
Ending date: October 2007
Last updated: October 3, 2006
|
